Ralph Gottwald

[Ralph Gottwald @RalphGottwald]

@The5Greeks @ReplyGuy_Cap My first buys were in the 2's a few years ago. $7 average now. Once we get a Parkinson drug approval I see it hitting $50 and will start liquidating. I see this happening in 2028/2029 time frame.

[Ralph Gottwald @RalphGottwald]

@jjacobpeterson I have a lot of $clpt and I did add today. It is hard to imagine that if one of their partners proves their drug can cure epilepsy or dramatically slow Parkinson's disease that there wouldn't be a path to market established.

[Ralph Gottwald @RalphGottwald]

@GabrieleIserani Thanks for the info, does this mean you are shorting the stock?

[Ralph Gottwald @RalphGottwald]

@adamfeuerstein What a terrible response. I followed his lead on $CLPT buying in the $2's and have done pretty well since then with much more to come. I'm confident $NWBO will work out too. I'm in at $.29 avg for a lot of shares.

[Ralph Gottwald @RalphGottwald]

@RIP_GOP1234 It's gotta be $NWBO.

[Ralph Gottwald @RalphGottwald]

@ManRam930 The Trend is your Friend.

[Ralph Gottwald @RalphGottwald]

@LisainNJUSA @RichFairgrieve @Richard67637214 @UCLA @ThomasOwenMcCa1 That is great news Lisa. Thanks for sharing.

[Ralph Gottwald @RalphGottwald]

@SeB_Inv Very nice summary. I've been in $CLPT since MRI Intervention days with my initial buys in the $2 range. Current cost avg at $7 and ready to start buying again. Fully expect it to hit $100 within the next 10 years.

[Ralph Gottwald @RalphGottwald]

@alphavestcap Where is the part about not attending ASCO? The ASCO 2025 website shows them to have one of the bigger booths at the show. Close to the break area where food is served.

[Ralph Gottwald @RalphGottwald]

@Tiggersdad2 @AndrewEcker829 @Bullsey71772634 Is @tiggersdad2 really Douggie? It sure seems so. Why are you constantly bashing $NWBO? What is your motivation? Why not move on and focus on other things? I don't get it...

[Ralph Gottwald @RalphGottwald]

@d_stock07734 @NijoCastle @biggercapital You know Dr. Linda Liau (DC Vax inventor) sits on Clearpoint's board don't you? She also currently acts as a consultant to NorthWest Bio. All of that isn't by accident. I own both. $NWBO and $CLPT

[Ralph Gottwald @RalphGottwald]

@aintnothing1234 It may be addition thru subtract. I've always felt that $CLPT has been slow roll in getting new products out to market. Maybe new person can be more aggressive at generating sales. Neurochase seemingly is years behind and is a small company. Who would big Pharm trust more.

[Ralph Gottwald @RalphGottwald]

@Sonicconcept1 18K purchased in E-trade account Friday 10:00 or so.

[Ralph Gottwald @RalphGottwald]

@investoryan @aintnothing1234 I think your assumptions are good too. I want to hear them confirm guidance of FCF positive by Q4. I think that is important.

[Ralph Gottwald @RalphGottwald]

@LisainNJUSA Thank you for sharing. As a $NWBO long, I appreciate these updates and am praying for your husband's speedy recovery with this treatment. Your documenting this helps negate the naysayers. God Bless.

[Ralph Gottwald @RalphGottwald]

@alphavestcap I've wondered that too. Looking forward to the algorithms being set to increase share price instead of decreasing.

[Ralph Gottwald @RalphGottwald]

@ArbakiMessi @SECGov @biggercapital He's also a big holder of $CLPT which has been on quite a run and is continuing to go higher. Key is you have to do your own research and not blindly follow someone.

[Ralph Gottwald @RalphGottwald]

@gmc_thoughts A few of us tried to talk sense into him, but he wasn't having it. Long runway for $CLPT.

[Ralph Gottwald @RalphGottwald]

@NeuroStockDoc Hello Neurodoc. Thanks for sharing your port. We share $CLPT and $SMTI. Both are doing well. Have you considered $STXS. I own it and think I'm going to go bigger into it. Robotic Surgery. Love to get your opinion. Thank you.

[Ralph Gottwald @RalphGottwald]

@exosome @JdBell20 Dr. Tom. I enjoy reading your posts and you add validity to the $NWBO value chain. Why wouldn't you want to own the stock though? BTW, I'm a recent $NWBO long.